翰森制药与罗氏达成ADC组合重磅授权：4亿美元首付款+1.1亿美元周年付款+超150亿美元里程碑

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility
for the contents of this announcement, make no representation as to its accuracy or completeness and expressly
disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the
contents of this announcement.

Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司
(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

INSIDE INFORMATION
STRATEGIC COLLABORATION AND LICENSE
AGREEMENT WITH ROCHE
This announcement is made by Hansoh Pharmaceutical Group Company Limited (the “Company”,
together with its subsidiaries, the “Group”) pursuant to Rule 13.09 of the Rules Governing the
Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the
inside information provision (as defined in the Listing Rules) under Part XIVA of the Securities
and Futures Ordinance (Cap. 571).
The board (the “Board”) of directors (the “Directors”) of the Company is pleased to announce
that, on October 17, 2026, Shanghai Hansoh Biomedical Co., Ltd.* (上海翰森生物醫藥科技有
限公司), Changzhou Hansoh Pharmaceutical Co., Ltd.* (常州恒邦藥業有限公司) and Hansoh
Bio, LLC (collectively, “Hansoh”), all being wholly-owned subsidiaries of the Company, entered
into a strategic collaboration and license agreement (the “Collaboration Agreement”) with F.
Hoffmann-La Roche Ltd (“Roche”).
The strategic collaboration spans a broad portfolio of Antibody-Drug Conjugate (“ADC”) programs
(the “Programs”), comprising two preclinical Hansoh ADC programs and multiple ADC programs
based on Roche-proposed targets powered by Hansoh’s proprietary ADC technology platform.
Under the Collaboration Agreement, Hansoh will lead the early development of the Programs up to
the completion of global Phase Ia clinical trials. Roche will be responsible for further developing
the Programs worldwide (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan).
Hansoh will retain all rights to develop, register and commercialize the Programs within the
Chinese Mainland, Hong Kong, Macau and Taiwan.
Hansoh will receive an upfront payment of US$400 million as well as a first anniversary payment
of US$110 million, and be eligible to receive potentially more than US$15 billion in milestone
payments associated with the development, regulatory approval and commercialization of the
Programs, as well as tiered royalties on potential future product sales. Under the Collaboration
Agreement, Hansoh has the option to select up to two programs and contribute to their development
outside the Chinese Mainland, Hong Kong, Macau and Taiwan and, in return for such contribution,
become eligible to receive incremental upside from the commercialization of these two programs
in the United States.

1

F. Hoffmann-La Roche Ltd is a subsidiary of Roche Holding AG, which is listed on the SIX Swiss
Exchange in Switzerland. Roche was founded in Basel, Switzerland in 1896 and today is a leading
provider of transformative medicines and diagnostics for millions of people in over 150 countries
around the world.
The Board believes that entering the Collaboration Agreement is in the best interests of the
Company and its shareholders as a whole. The Company will also leverage on this opportunity to
maximize the scientific and commercial value of the Group’s technology platforms.
LISTING RULES IMPLICATION
To the best of the Directors ’ knowledge, information and belief having made all reasonable
enquiry, Roche and its ultimate beneficial owner are independent of, and are not connected
with, the Company and its connected persons (as defined in the Listing Rules). The transactions
contemplated under the Collaboration Agreement are of a revenue nature in the ordinary and usual
course of business of the Group and do not constitute any notifiable transactions or connected
transactions of the Company under the Listing Rules.
The Collaboration Agreement is subject to customary closing conditions, including
the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust
Improvements Act in the United States, and any necessary regulatory filings. The
shareholders and potential investors of the Company are advised to exercise due care when
dealing in the shares of the Company.
By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady
Hong Kong, October 19, 2026

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady
and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin
Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent
non-executive directors.
*

For identification purposes only

2